BeiGene to Present at Upcoming Investor Conferences
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences: The 6th Annual Cowen IO
Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences: The 6th Annual Cowen IO
BRUKINSA is the first and only Bruton's Tyrosine Kinase (BTK) inhibitor for marginal zone lymphoma approved in the European Union BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology
BRUKINSA received Marketing Authorization as a treatment for rare blood cancers in six countries in Central and South America BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology
14.10.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Committee ... Seite 1
12.10.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA ... Seite 1